Contribution of MMP2 Promoter Genotypes to Oral Cancer Susceptibility, Recurrence and Metastasis in Taiwan

• Published in: Anticancer research Vol. 38; no. 12; pp. 6821 - 6826
• Main Authors: Tsai, Chia-Wen, Hsu, Huai-Mei, Wang, Yun-Chi, Chang, Wen-Shin, Shih, Liang-Chun, Sun, Kuo-Ting, Hung, Yi-Wen, Yang, Yi-Chin, Gong, Chi-Li, Bau, DA-Tian
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.12.2018
• Subjects: Adult; Aged; Alcohols; Alleles; Cancer; Case-Control Studies; Cigarettes; Confidence intervals; Control methods; Dental materials; Differential distribution; Female; Gelatinase A; Genetic Predisposition to Disease; Genotypes; Health risk assessment; Health risks; Humans; Lymph nodes; Male; Matrix Metalloproteinase 2 - genetics; Metalloproteinase; Metastases; Metastasis; Middle Aged; Mouth Neoplasms - epidemiology; Mouth Neoplasms - genetics; Mouth Neoplasms - pathology; Neoplasm Metastasis; Neoplasm Recurrence, Local - genetics; Oral cancer; Patients; Polymorphism, Single Nucleotide; Promoter Regions, Genetic - genetics; Proteins; Recurrence; Risk; Risk taking; Smoking; Taiwan - epidemiology; Taiwan; Genotype; polymorphism; metastasis; MMP2; oral cancer; Taiwan
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.13055

Metalloproteinase 2 (MMP2) is a multi-functional protein which has been shown to be up-regulated in patients with oral cancer, especially those with lymph node metastasis. However, the association of MMP2 genotype with oral cancer risk or metastatic behavior is unknown. This study aimed to evaluate the role of MMP2 promoter 1306 and -735 genotypes in the risk of oral cancer and metastasis. In this case-control study, MMP2 promoter 1306 (rs243865) and -735 (rs2285053) genotypes and their interaction with consumption of areca, cigarettes, and alcohol in determining oral cancer risk were investigated among 788 patients with oral cancer and 956 gender-matched healthy controls. In addition, their role in oral cancer metastasis were also examined. The distribution of CC, CT and TT for MMP2 promoter 1306 genotype was 79.0, 20.1 and 0.9% in the oral cancer group and 68.7, 29.2 and 2.1% in the non-cancer control group, respectively (p for trend=4.3E-6). The allelic frequency distributions showed that the variant T allele of MMP2 promoter 1306 conferred lower oral cancer susceptibility than the wild-type C allele (odds ratio=0.61, 95% confidence interval=0.50-0.75, p=1.1E-6). As for the MMP2 -735 genotypes, there was no differential distribution in genotypic or allelic frequencies. The variant CT and TT genotypes were also associated with lower metastasis rates within 5 years among the patients with oral cancer (odds ratio=0.34, 95% confidence interval=0.15-0.80, p=0.0102). The CT and TT genotypes of MMP2 promoter 1306 may have a protective effect on oral cancer susceptibility and metastasis risk within 5 years for Taiwanese. They may serve as predictive markers for oral cancer in precise medical practice.